TABLE 1.
For comparison among four groups (female and male with/without APOE ε4) Kruskal‐Wallis and chi‐square tests were applied to test for significance
| Sex | Female | P‐val | Male | P‐val | P‐val | ||
|---|---|---|---|---|---|---|---|
| APOE ε4 carrier | NO | YES | APOE ε4 in female (YES/NO) | NO | YES | APOE4 in male (YES/NO) | Comparing gender and APOE carrier |
| Number of patients | 101366 | 35299 | 85763 | 29899 | .905 | ||
| Ethnicity (%) | |||||||
| Asian | 1507 (1.5) | 282 (0.8) | 1751 (2.0) | 384 (1.3) | .065 | ||
| Black | 944 (0.9) | 471 (1.3) | 692 (0.8) | 361 (1.2) | .604 | ||
| Chinese | 308 (0.3) | 59 (0.2) | 173 (0.2) | 33 (0.1) | .985 | ||
| Mixed | 418 (0.4) | 151 (0.4) | 288 (0.3) | 100 (0.3) | .791 | ||
| Other ethnic group | 754 (0.7) | 201 (0.6) | 538 (0.6) | 139 (0.5) | .801 | ||
| Not known | 316 (0.3) | 110 (0.3) | 424 (0.5) | 163 (0.5) | .490 | ||
| White | 97120 (95.8) | 34025 (96.4) | 81897 (95.5) | 28719 (96.1) | .919 | ||
| Mean age at recruitment (SD) | 61.93 (4.1) | 61.9 (4) | .206 | 62.22 (4.1) | 62.24 (4.1) | .344 | <. 0007* |
| University/college degree: YES (%) | 40586 (40) | 9377 (26.6) | .007 | 40763(47.5) | 9465(31.7) | .084 | <. 0007* |
| Townsend deprivation index (SD) | −1.55 (2.9) | −1.6 (2.9) | .004 | −1.52(3) | −1.51(3) | .701 | .645 |
| Cognitive measures (SD) | |||||||
| Fluid Intelligence | 5.81 (2.1) | 5.83 (2) | .261 | 6.09 (2.2) | 6.08 (2.2) | .623 | <. 0007* |
| Paris test–1st round | 0.65 (1.3) | 0.66 (1.3) | .356 | 0.57 (1.3) | 0.58 (1.3) | .089 | <.0007* |
| Paris test–2nd round | 4.46 (3.4) | 4.48 (3.5) | .151 | 4.51 (3.7) | 4.45 (3.6) | .021 | <.0007* |
| Reaction test | 590.86 (122.3) | 589 (119.2) | .019 | 570.07 (119.5) | 572.24 (120.9) | .003 | <.0007* |
| Diagnoses (%) | |||||||
| AD dementia | 110 (0.1) | 116 (0.3) | <.0007* | 112 (0.1) | 106 (0.4) | <. 0007* | .192 |
| Acute myocardial infraction | 220 (0.2) | 154 (0.4) | <.0007* | 397 (0.5) | 175 (0.6) | <. 0007* | <.0007* |
| Atrial fibrillation | 1578 (1.6) | 444 (1.3) | <.0007* | 5450 (6.4) | 1449 (4.8) | <. 0007* | <.0007* |
| Hypertension | 5717 (5.6) | 1381 (3.9) | .144 | 10323 (12) | 2476 (8.3) | .073 | <.0007* |
| Diabetes | 32939 (32.5) | 7685 (21.8) | .441 | 36681 (42.8) | 8815 (29.5) | <. 0007* | <.0007* |
| Acute cerebrovascular | 7009 (6.9) | 1492 (4.2) | .003 | 11025 (12.9) | 2375 (7.9) | .002 | <.0007* |
| Disease | 1056 (1) | 233 (0.7) | .537 | 1760 (2.1) | 460 (1.5) | .018 | <.0007* |
| Coronary atherosclerosis | 6651 (6.6) | 1675 (4.7) | .002 | 16684 (19.5) | 4339 (14.5) | <. 0007* | <.0007* |
| Disorders lipid metabolism | 12057 (11.9) | 3616 (10.2) | <.0007* | 19270 (22.5) | 5333 (17.8) | <. 0007* | <.0007* |
| Angina | 5845(5.8) | 1502 (4.3) | <.0007* | 10855 (12.7) | 2849 (9.5) | <. 0007* | <.0007* |
| Statin use (%) | 22376 (22.1) | 6728 (19.1) | <.0007* | 36020 (42) | 9851 (32.9) | <.0007* | <.0007* |
| Simvastatin use | 16180 (16) | 4665 (13.2) | <.0007* | 25858 (30.2) | 6777 (22.7) | <.0007* | <.0007* |
| Atorvastatin use | 3913 (3.9) | 1281 (3.6) | <.0007* | 6400 (7.5) | 2003 (6.7) | <.0007* | <.0007* |
| Pravastatin use | 716 (0.7) | 224 (0.6) | <.0007* | 1135 (1.3) | 295 (1) | .072 | <.0007* |
| Rosuvastatin use | 844 (0.8) | 325 (0.9) | <.0007* | 1110 (1.3) | 397 (1.3) | <.0007* | <.0007* |
For the comparison of APOE ε4 carriers within females and males t test and and chi‐square were used. We corrected the results for multiple testing using alpha = 0.05/66 = 0.00076, where 66 is the number of test performed.
Ns P‐val > .0007, * P‐val < = .0007.
Abbreviations: AD, Alzheimer's disease; APOE, apolipoprotein E; SD, standard deviation.